CME Presentations

Young Adults with Hodgkin Lymphoma



  • Lisa Roth, MD

    Lisa Roth, MD

    Lisa Roth, MD

    Director, Pediatric Oncology

    Lisa Roth, MD, is an Associate Professor of Pediatrics in the Division of Pediatric Hematology/Oncology at Weill Cornell Medical College. Also, she serves as the Director of the Pediatric Oncology Program and the Adolescent and Young Adult Lymphoma Program at Weill Cornell Medicine/New York Presbyterian Hospital. Dr. Roth serves as the Vice Chair for the Hodgkin Lymphoma Committee in the Children’s Oncology Group. Her laboratory research focuses on identifying novel therapeutic targets for pediatric lymphomas such as aggressive B-cell non-Hodgkin lymphoma. Dr. Roth’s laboratory work is closely tied to her clinical research where she is leading several national clinical trials focused on advancing therapy for children, adolescents, and young adults with Hodgkin and non-Hodgkin lymphoma.
  • Matthew Ehrhardt

    Matthew Ehrhardt

    Matthew Ehrhardt

    MD, MS

    Matthew Ehrhardt, MD, MS is an associate member in the Division of Cancer Survivorship at St. Jude Children’s Research Hospital, where he specializes in the care of children newly diagnosed with Hodgkin and non-Hodgkin lymphomas and long-term childhood cancer survivors. Dr. Ehrhardt’s clinical research is focused on the long-term effects of childhood cancer treatment and surveillance guideline development, dissemination, and utilization. He is the co-chair of the Children’s Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers and an active participant in the International Guideline Harmonization Group for Late Effects of Childhood Cancer.

CME Information

Global Logo PQH Logo

Charting the Course for Pediatric and Young Adults with Hodgkin Lymphoma

Jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC, in collaboration with the National Organization for Rare Disorders (NORD).


This activity is supported by independent educational grants from Bristol-Myers Squibb, Merck & Co., Inc., and Seagen, Inc.


This activity was released on January 30, 2024 and is valid until January 30, 2025. Requests for credit must be made no later than January 30, 2025.


The primary target audience for this activity are Hematology-oncologists, pediatric hematologists/oncologists, hematologists, nurse practitioners, physician assistants, medical oncologists, oncology pharmacists, and other health care providers (HCPs) involved in the care of patients with Hodgkin lymphoma.


While rare in the pediatric population, Hodgkin lymphoma (HL) constitutes approximately 40% of all lymphomas that present during childhood and is the most common malignancy in adolescents and young adults. Pediatric HL is highly sensitive to treatments for adults, but long-term toxicity is worse in developing individuals. Therefore, ongoing clinical trials for pediatric HL are attempting to reduce long-term toxicity and increase efficacy.

Join a panel of hematologists and oncologists to review available treatment options and receive practical guidance on the management of young patients with HL. Experts will discuss regimen selection, the management of complications, and the unique treatment challenges associated with managing pediatric and young-adult populations. Clinicians will be brought up to date with the latest evidence across all aspects of care to make informed and confident management decisions and achieve long-term treatment goals.


After completing this activity, the participant should be better able to:
  • Review the efficacy and safety of current and emerging therapeutic regimens for pediatric and young-adult patients with Hodgkin lymphoma in the frontline and relapsed/ refractory settings
  • Identify best practices for the proactive identification and management of adverse events associated with current and emerging therapeutic regimens
  • Discuss multidisciplinary approaches to survivorship and follow-up care plans for pediatric and young-adult patients with Hodgkin lymphoma



In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 60 minutes to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Faculty Conflicts of Interest
Lisa Giulino Roth, MD
Director, Pediatric Oncology
Director, Adolescent and Young Adult Lymphoma Program
Weill Cornell Medical College
Vice Chair, Hodgkin Lymphoma Committee, Children’s Oncology Group
Dr. Lisa Roth, faculty for this educational activity, has the following relevant financial relationships:
Consultant, Advisor, Speaker: Merck & Co.
Researcher: Seagen, Inc.
Matthew Ehrhardt, MD, MS
Associate Member, Department of Oncology
St. Jude Children's Research Hospital
Dr. Matthew Ehrhardt, faculty for this educational activity, has no relevant financial relationships.
Elizabeth Stone
Refractory Hodgkin's Lymphoma patient
Elizabeth Stone, a vignette speaker for this activity, has no relevant financial relationships.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support:

For additional information about the accreditation of this activity, please visit

Technical Support:

For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at